Alfred E. Tiefenbacher (GmbH & Co. GmbH)
Ms Anna Bettina GoosBusiness Development & Licensing Manager
Bannert Manlik Consultants GmbH
Specialized Pharma M&A Boutique operating since 1991 globally
Ms Ulrike DäxlProject Manager
Boehringer Ingelheim Corporate Center GmbH
Mr Juergen BeckHead of Strategic Transactions & Alliance Management
Dr. M. Newzella GmbH
Dr. M. Newzella GmbH is an international personnel and business consulting company active within the fields of pharmaceuticals and health care and specializing in the areas of Executive Search, Merger & Acquisition and Product & Licensing.
Thanks to its 35 years of branch experience, Dr. Newzella Consulting has built up an extensive international network of excellent business contacts and has far-reaching knowledge of both companies and markets to supports its clients with individual, flexible and high performance services.
Dr Christoph NewzellaManaging Partner & Director Management Consulting
Dr Matthias NewzellaManaging Partner, Director Management Consulting & Head of Executive Search
GeneriNobel is a privately owned pharmaceutical company, based in Germany, which outlicenses generic drugs (Rx) and OTC developments for the European market.
Key therapeutic areas are cardiovascular diseases, central nervous system and metabolism. GeneriNobel has a focus on dossier development, registration and outlicensing of generic / OTC drugs and represents the marketing authorization / dossier portfolio of its partner, the turkish multinational pharmaceutical company Nobel Ilaç (own R&D and manufacturing of APIs and finished products).
* Out-licensing of generic / OTC drugs (dossiers) at an advanced stage of regulatory approval procedure, e. g. Rosuvastatin.
* Out-licensing of generic / OTC drugs (marketing authorisations / dossiers) with granted marketing authorisations in Germany and which are available for further registration procedures in Europe, e. g. Solifenacin, Rasagiline, Duloxetine, Aripiprazole, Memantine, Irbesartan and Irbesartan-HCTZ, Sildenafil, Escitalopram, Pantoprazole and Omeprazole.
We are interested in:
Marketing and Sales companies who are interested to in-license products of our Portfolio.
We are NOT interested in:
* regulatory service providers, IP service providers, legal advisors, APIs.